Literature DB >> 15214790

Conjugates of gadolinium complexes to bile acids as hepatocyte-directed contrast agents for magnetic resonance imaging.

Pier Lucio Anelli1, Luciano Lattuada, Vito Lorusso, Giovanna Lux, Alberto Morisetti, Pierfrancesco Morosini, Michele Serleti, Fulvio Uggeri.   

Abstract

A series of structurally different Gd(III) conjugates incorporating a bile acid moiety have been prepared. Polyaminopolycarboxylic ligands such as diethylenetriaminepentaacetic acid (DTPA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid (DOTA) have been selected as chelating subunit for the Gd(III) ion. Cholic acid, cholylglycine, and cholyltaurine have been incorporated as the bile acid moieties. In first generation conjugates the Gd(III) complex is linked to the carboxyl group of cholic acid. Second generation conjugates feature the attachment of the Gd(III) complex to the 3 position of the steroidic backbone of the bile acid. Finally, in third generation conjugates the Gd(III) complex is attached to the epsilon nitrogen atom of cholyllysine. The conjugates are eliminated through the biliary route to a various extent (7.5 to 77% in rats) according to their structural features. Among the most promising terms, a second generation conjugate in which the Gd(III) complex is linked to cholic acid through the 3alpha hydroxy group seems to enter hepatocytes using the Na(+)/taurocholate transporter. Noticeably, some of the second generation conjugates are characterized by very high tolerabilities (LD(50) up to 9.5 mmol/kg) after intravenous administration in mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15214790     DOI: 10.1021/jm0310683

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Strategies for the preparation of bifunctional gadolinium(III) chelators.

Authors:  Luca Frullano; Peter Caravan
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

Review 2.  Role of the intestinal bile acid transporters in bile acid and drug disposition.

Authors:  Paul A Dawson
Journal:  Handb Exp Pharmacol       Date:  2011

3.  SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies.

Authors:  G Vaidyanathan; B J White; D J Affleck; X G Zhao; P C Welsh; D McDougald; J Choi; M R Zalutsky
Journal:  Bioorg Med Chem       Date:  2012-10-29       Impact factor: 3.641

Review 4.  Exploitation of bile acid transport systems in prodrug design.

Authors:  Elina Sievänen
Journal:  Molecules       Date:  2007-08-16       Impact factor: 4.411

5.  Increase of leishmanicidal and tubercular activities using steroids linked to aminoquinoline.

Authors:  Luciana Mr Antinarelli; Arturene Ml Carmo; Fernando R Pavan; Clarice Queico F Leite; Adilson D Da Silva; Elaine S Coimbra; Deepak B Salunke
Journal:  Org Med Chem Lett       Date:  2012-05-02

Review 6.  Bile acid binding protein: a versatile host of small hydrophobic ligands for applications in the fields of MRI contrast agents and bio-nanomaterials.

Authors:  Katiuscia Pagano; Simona Tomaselli; Serena Zanzoni; Michael Assfalg; Henriette Molinari; Laura Ragona
Journal:  Comput Struct Biotechnol J       Date:  2013-12-08       Impact factor: 7.271

7.  Targeted T1 Magnetic Resonance Imaging Contrast Enhancement with Extraordinarily Small CoFe2O4 Nanoparticles.

Authors:  Dominique Piché; Isabella Tavernaro; Jana Fleddermann; Juan G Lozano; Aakash Varambhia; Mahon L Maguire; Marcus Koch; Tomofumi Ukai; Armando J Hernández Rodríguez; Lewys Jones; Frank Dillon; Israel Reyes Molina; Mai Mitzutani; Evelio R González Dalmau; Toru Maekawa; Peter D Nellist; Annette Kraegeloh; Nicole Grobert
Journal:  ACS Appl Mater Interfaces       Date:  2019-02-08       Impact factor: 9.229

Review 8.  Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver.

Authors:  Julia Greiser; Wolfgang Weigand; Martin Freesmeyer
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.